

**Title:** Complete Inhibition of *Clostridium difficile* with a Probiotic Juice Beverage

**Short Title:** Inhibition of *C. diff* with a Probiotic Juice

**Authors:** Howard F. Robins<sup>1\*</sup> and A. Reza Kamarei <sup>2</sup>

1) Chief Medical Officer, Doctor's Biome, Hauppauge, NY 11788

2) Chief Science & Technology Officer, Doctor's Biome, Hauppauge, NY 11788

**\*Corresponding author:** Dr. Howard F. Robins

Doctor's Biome (Newgen 27 LLC)

80 Davids Dr., Unit 2

Hauppauge, NY 11788

Phone: (631) 240-3066

Cell: (516) 967-1009

[drrobins@doctorsbiome.com](mailto:drrobins@doctorsbiome.com)

## ABSTRACT

**Background & Aims:** Clostridium difficile (“*C. difficile*” or “*C. diff*”) is a Gram-positive, spore-forming, anaerobic, motile bacterium which produces two types of toxins, enterotoxin A and cytotoxin B. Clostridium difficile Infection (CDI) causes life-threatening diarrhea which is usually a side-effect of taking antibiotics. *C. diff* can easily spread from person to person and is considered a major health threat. In 2017, there were an estimated 223,900 cases in hospitalized patients and 12,800 deaths in the United States. There has been considerable scientific research in using various probiotic strains against *C. diff* with diverse observations and inconsistent results. Our first goal was to develop an “optimum probiotic product” to inhibit growth and pathogenicity of *C. diff*. Our second goal was to prove an inhibitory effect of bioactive compounds (secreted by the 15 strains of probiotic bacteria into the juice) on *C. diff*.

**Methods:** For optimum profile of probiotics, we considered positive results from specific strains in the published literature and commercially-available probiotic bacteria from credible global suppliers. As a result, we chose a blend of five strains of Bifidobacteria and ten strains of Lactobacilli. For an optimum carrier, we chose a proprietary blend of organic green vegetable and fruit juices. Upon culture propagation and strain verification of Clostridium difficile ATCC #9689, inoculum was prepared using reinforced clostridial broth and a sample was prepared using centrifuged, microfiltered supernatant of Doctor’s Biome Colon Health (DBCH). The inoculated *control* was serially diluted with sterile 0.1% Peptone Buffer. The inoculated *sample* was serially diluted with the centrifuged, filtered supernatant of DBCH. The serially diluted control and diluted

sample were transferred to agar plates and incubated anaerobically at 35-37°C for 18-24 hours.

**Results:** Serially diluted agar plates of the control showed presence of *C. diff* colony forming units, which were biochemically identified via VITEK ANC. Serially diluted agar plates of the sample did not show any *C. diff* colony forming units due to the inhibitory effect of the DBCH bioactive compounds.

**Conclusions:** We believe inhibition of *C. diff* by DBCH probiotics should be considered from both a quantitative and qualitative points of view. From a quantitative point of view, a general mechanism of microbial inhibition is through the “competitive exclusion principle”. This means that when two species compete in a limited environment (e.g., colon) and compete for the same limited amount of nutrients, the species that has advantage over the others (e.g., larger numbers) will dominate the environment and lead to the exclusion of the weaker competitor. From a qualitative point of view, it seems that the chosen blend of Bifidobacteria and Lactobacilli have released some bioactive compounds into the juice that has completely inhibited growth of *C. diff*. We conclude that the bioactive compounds secreted from the 15 probiotic strains into the organic vegetable and fruit juice has played a decisive inhibitory role against growth of *C. diff*.

**Key Words:** Clostridium difficile, C. difficile, C. diff., Clostridium difficile infection (CDI), Probiotics, Multi-Strain Probiotics, Liquid Probiotics

## INTRODUCTION

*Clostridium difficile*, also known as “*C. difficile*” or “*C. diff*” is a Gram-positive, spore-forming, anaerobic, motile bacterium (Fig 1). *Clostridium difficile* cells show optimum growth on blood agar at human body temperatures in the absence of oxygen. *Clostridium difficile* produces two types of toxins, enterotoxin A and cytotoxin B.

*C. difficile* is a bacterium that causes life-threatening diarrhea. It is usually caused as an adverse effect of taking antibiotics. It is considered a major health threat and listed as an “Urgent Threat” by the Center for Disease Control (CDC) [1]. According to the CDC symptoms may begin within a few days or several weeks after beginning or following the taking of antibiotics or when people touch surfaces that are contaminated with feces from an infected person. Symptoms of *Clostridium difficile* Infection (CDI) include diarrhea, loose or watery stools lasting for several days, fever, stomach tenderness, loss of appetite and nausea. Frequent recurrent and duplicate episodes are common with one in six patients with CDI occurring again within two to eight weeks [1].

These infections are common in people 65 and older (80+%) and in children who take antibiotics and receive outpatient medical care or people who stay in hospitals and nursing homes for a long period of time [1,2]. Also, it is common in patients with weakened immune systems on antibiotics or with previous infection with *C. diff*. One out of eleven patients diagnosed with CDI will die within a month [1].

The estimated national burden of *C. difficile* infection (CDI) was 476,400 cases in 2011 and 462,100 in 2017 with an average number of deaths around 28,000 per year [3].

CDI puts a tremendous strain on the healthcare system. The total financial burden of CDI inpatient management was estimated to be \$5.4-6.3 billion USD per year. This includes 2.4 million days of hospital stays and growing in number yearly [3-7].

With the increased use of appropriate and inappropriate prescriptions of antibiotics both in hospital and outpatient care the financial burden from CDI has risen over the past decade [7-10].

The scientific definition of the term ‘probiotic’ was proposed in a 2001 joint report of the Food and Agriculture Organization of the United Nations and the World Health Organization (FAO/WHO), and confirmed by an expert panel convened by International Scientific Association for Probiotics and Prebiotics (ISAPP) held in 2013. The currently accepted definition of probiotics is: “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.” This means if the microorganisms are not “live”, they cannot be considered probiotic and if their amount is not adequate enough to confer a health benefit, they cannot be considered probiotic either.

A review of the literature shows it is replete with hundreds of published papers showing various positive and some mixed results on the use of specific probiotic strains to help prevent and help treat CDI [11-16].

The probiotics used in most of the consumer available preparations are usually taken from a limited range of organisms. As this area of study has become more important and prevalent, new strains have come under investigation.

“Next Generation Probiotics” (NGP) are bacteria that due to their development act as live biotherapeutic products and lend themselves to act more like pharmaceuticals than traditional food supplements [17,18].

Despite the above findings reported in the literature, McDonald *et al* in 2017 *update on Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children*, using earlier publications up to 2013 and referring to issues such as differences in probiotic formulations studied, duration of probiotic administration, definitions of CDI, duration of study follow-up, inclusion of patients not typically considered at high risk for CDI, and the potential for organisms in probiotic formulations which can cause infections in hospitalized patients, concluded that there is insufficient data at this time to recommend administration of probiotics for primary prevention of CDI outside of clinical trials of probiotics for primary prevention of CDI. Yet the literature is replete with numerous studies showing that specific strains of patented bacteria have had beneficial results in the prevention and treatment of CDI.

The Harvard School of Public Health says “Because probiotics fall under the category of supplements and not food, they are not regulated by the Food and Drug Administration in the U.S. This means that unless the supplement company voluntarily discloses information on quality, such as carrying the USP seal that provides standards

for quality and purity, a probiotic pill may not contain the amounts listed on the label or even guarantee that the bacteria are alive and active at the time of use.”[19].

Several studies have been performed in an attempt to find a way to improve survival of probiotics before reaching the large intestine with limited and minimal success. This is one of the main concerns over capsule, powder, tablet and spore probiotics. Less than 59% survival using unique and somewhat expensive measures have been employed, though rarely found and used in most probiotic preparations currently available [20-25].

The FDA states “Many dietary supplements, often marketed as “probiotics,” include claims that the live microbial ingredient, formulated in adequate amounts, will confer a health benefit on consumers. The weight of microbial dietary ingredient in a product represents the product’s total cellular mass, consisting of both live and dead microorganisms, and therefore does not necessarily correlate with the number of viable microorganisms in that product.” [26].

### **Aims of the Study**

It became evident that certain strains of NGP “Smart Bacteria” (SB) achieved consistently the best results in helping to prevent and assist in CDI amelioration along with the usual treatment regimens. SB can sense they're attached to our intestinal cells, and then remodel their expression of specific genes, including those involved in metabolism, to beneficially exploit our cells and colonize our gut [27-28].

Bacteria have evolved to develop remarkable systems that can sense neighboring cells called “target” cells, and can initiate upon contact a series of changes that enhance their ability to survive and grow at the expense of these “target” cells. Smart Bacteria do this by employing a mechanism called “Horizontal Gene Transfer” (HGT). This is a very interesting and complex mechanism. Simply put, HGT shares genetic material between organisms that are not in a parent-offspring relationship and is a widely recognized mechanism for adaptation in bacteria [29-34].

With this concern in mind, NGP SB’s were created to survive the stomach acids and digestive enzymes 80% or more [35]. Also, to ensure that they are “living” and thriving at the time of ingestion an appropriate environment and media, a 100% organic vegetable-fruit juice needed to be found meeting all these needs including the range of acidity needed for survival and growth. The NGP SB’s that were chosen needed to be compatible with each other so as not to overwhelm each other’s growth and benefits. They also needed to be in a sufficient number of Colony Forming Units (CFU) to repopulate the colon and attack the CDI effectively.

Considering diverse observations and inconsistent results of various probiotic strains on *Clostridium difficile*, it was not possible to choose one single, most effective strain for inhibition of *C. difficile*. Therefore, we decided to develop an “optimum probiotic product” to inhibit growth and pathogenicity of *C. difficile*. We named it *Doctor’s Biome Colon Health™* or DBCH (Fig 2). By definition, DBCH should have the optimum profile of probiotic bacteria and be an optimum carrier for the chosen probiotic bacteria.



The immediate goal of our study was to prove the inhibitory effect of DBCH bioactive compounds (secreted by the 15 strains of NG Smart probiotic bacteria in the juice) on *C. difficile*.

## **MATERIALS AND METHODS**

### **Optimum Profile of Probiotics**

Bifidobacteria and Lactobacilli are broadly recognized for their key roles in the human intestinal microflora throughout life. A high proportion of bifidobacteria and lactobacilli in the intestinal tract is considered beneficial to health. Considering the results of published literature mentioned above and reviewing commercially-available probiotic bacteria from credible global suppliers, we chose a blend of five strains of Bifidobacteria (Table 1a) and ten strains of Lactobacilli (Table 1b) from DuPont Nutrition & Biosciences.

### **Optimum Carrier**

In search of an optimum carrier (also known as excipients or medium), we chose a proprietary blend of organic green vegetable and fruit juices consisting of 100% organic, diluted, mint juice, cucumber juice, apple juice, lettuce juice, kale juice, celery juice and lemon juice. Sensory evaluation of DBCH (blend of probiotics in blend of organic juices) showed a pleasant taste of this product to consumers across the board. Furthermore, every batch of Doctor's Biome Colon Health is tested by an independent, FDA-registered accredited microbiology lab to confirm absence of pathogenic microorganisms.

## **Design of the Study**

### ***Culture Propagation and Strain Verification***

A sterile inoculating loop of *Clostridium difficile* ATCC #9689 was streaked onto a Reinforced Clostridial agar slant, broth tubes, and two Sheep Blood agar plates. The slant and broth tubes and one Sheep Blood agar plate were incubated anaerobically at 36-38°C for 48 ± 2 hours. The second Sheep Blood agar plate was incubated aerobically at 36-38°C for 48 ± 2 hours and served as the contamination check. Following incubation, the agar plates and tube were observed for colony growth and turbidity. The Sheep Blood agar plate incubated anaerobically was biochemically identified using the VITEK ANC card to verify purity.

### ***Inoculum Preparation***

A well isolated colony from the Sheep Blood agar plate was used to inoculate a Reinforced Clostridial broth, which was then incubated anaerobically at 36-38°C for 18 to 20 hours. Following incubation, the culture was stored overnight at 3 ± 1 °C.

### ***Sample Preparation***

Six, individually packaged, intact 2-ounce DBCH glasses were composited into a sterile 500 mL glass bottle under a laminar flow hood. This bottle was mixed by gentle swirling and stored at ambient temperature (20-25°C) until testing. At that time, the composited product was homogenized. Then 10 mL was pipetted into a test tube for a before (Fig 3) and after comparison photo with the centrifuged product. Following centrifugation at 4500 RPM for 15 minutes, the supernatant liquid was filtered through a 0.22 µm filter to ensure that the supernatant liquid was free of cells. A 10 mL portion was pipetted into a test tube and photographed (Fig 4). The filtered sample was used as

the test product **sample** and the 9 mL diluent tubes for its ten-fold serial dilution. The inoculated **control** was analyzed with sterile 0.1% Peptone Buffer.

### ***Test Procedure***

Test procedure was performed according to the Compendium of Methods for the Microbiological Examination of Foods, 5th Edition, Chapter 33, Section 33.7 (Editors: Yvonne Salfinger and Mary Lou Tortorello, American Public Health Association).

#### ***1. Control Test Procedure:***

The inoculum used for the sample test procedure was vortexed for 5 seconds. 1 mL of the inoculum was transferred to a 9 mL tube of 0.1% Peptone Buffer and vortexed for 5 seconds. This served as the  $10^{-1}$  dilution tube. 1 mL from the  $10^{-1}$  dilution tube was transferred in duplicate into sterile Petri Dishes. With the same pipet, 1 mL was transferred into a second 9 mL tube containing the 0.1% Peptone Buffer for the  $10^{-2}$  dilution tube and vortexed for 5 seconds. 1 mL from the  $10^{-2}$  dilution tube was transferred in duplicate into sterile Petri Dishes. With the same pipet, 1 mL was transferred into a third 9 mL tube containing the 0.1% Peptone Buffer for the  $10^{-3}$  dilution tube and vortexed for 5 seconds. Serial dilution was repeated until a  $10^{-8}$  dilution plate was reached. Approximately 20 mL of tempered (44-46°C) Reinforced Clostridial agar was added to the Petri Dishes and gently swirled to evenly disperse inoculum throughout the agar. After solidification, 15 mL of Reinforced Clostridial agar was overlaid onto each plate. The plates were incubated anaerobically in an upright position at 35-37°C for 18-24 hours.

#### ***2. Sample Test Procedure:***

The refrigerated anaerobic chamber containing the inoculum was equilibrated to ambient temperature prior to inoculation. The inoculum was vortexed for 5 seconds to homogenize. 1 mL of the inoculum was transferred to a 9 mL tube of the supernatant test sample and vortexed for 5 seconds. This served as the 10<sup>-1</sup> dilution tube. 1 mL from the 10<sup>-1</sup> dilution tube was transferred in duplicate into sterile Petri Dishes. With the same pipet, 1 mL was transferred into a second 9 mL tube containing the supernatant test sample for the 10<sup>-2</sup> dilution tube and vortexed for 5 seconds. 1 mL from the 10<sup>-2</sup> dilution tube was transferred in duplicate into sterile Petri Dishes. With the same pipet, 1 mL will be transferred into a third 9 mL tube containing the supernatant test sample for the 10<sup>-3</sup> dilution tube and vortexed for 5 seconds. Serial dilution was repeated until a 10<sup>-8</sup> dilution plate was reached. Approximately 20 mL of tempered (44-46°C) Reinforced Clostridial agar was added to the Petri Dishes and gently swirled to evenly disperse inoculum throughout the agar. After solidification, 15 mL of Reinforced Clostridial agar was overlaid onto each plate. The plates were incubated anaerobically in an upright position at 35-37°C for 18-24 hours.

## RESULTS

Following incubation, photographs were taken of the serially diluted agar plates of the **control** to visually show presence of Clostridium difficile colony forming units (Fig 5). The plates which exhibited less than 300 colonies were enumerated and representative colonies for Clostridium difficile were biochemically identified via VITEK ANC (Table 2).

Similarly, following incubation, photographs were taken of the serially diluted agar plates of the **sample** to visually show absence of Clostridium difficile colony

forming units due to the inhibitory effect of the DBCH bioactive compounds (Fig 6 and Table 2).

## DISCUSSION & CONCLUSION

The obtained results of our *in-vitro* study are consistent with several published investigations in PubMed. We believe inhibition of *C. difficile* by DBCH probiotics should be considered from both quantitative and qualitative points of view:

From a quantitative point of view, a general mechanism of microbial inhibition is through the “competitive exclusion principle”. This means that when two species compete in a limited environment (e.g., colon) and compete for the same limited amount of nutrients, the species that has advantage over the others (e.g., larger numbers) will dominate the environment and lead to the exclusion of the weaker competitor. For example, in our study the probiotic dose of 27 billion live and active Colony Forming Units (CFU) for a daily serving of DBCH is considered among the higher quantities commercially available.

From a qualitative point of view, it seems that the chosen blend of Bifidobacteria and Lactobacilli have functioned in a complementary, additive and possibly synergistic way to completely inhibit growth of *C. difficile*. In other words, the chosen probiotics have released some bioactive compounds into the juice that has inhibited growth of *C. difficile*. One such compound could possibly be lactic acid (and possibly other organic acids) which can reduce the pH of the environment to an acidic range unfavorable for spore germination and/or growth of *C. difficile*. We can conclude that the bioactive compounds secreted from the chosen 15 probiotic strains into the organic vegetable and fruit juice has played a decisive inhibitory role against growth *C. difficile*.

The combined quantitative and qualitative properties of juice-based DBCH is expected to positively and impressively impact prevention and/or treatment of CDI.

Based on these results, and in line with the recent guidelines of American Gastroenterological Association on the role of probiotics in the management of gastrointestinal disorders [36], a prospective, randomized, double-blind clinical trial (based on Good Clinical Practice) on the safety and efficacy of DBCH for CDI patients is warranted.



## REFERENCES

1. Center for Disease Control: Healthcare Associated Diseases-Community Interface (HAIC).
2. Cost-effective analysis of oral antibiotics for the prevention of *Clostridium difficile*-associated diarrhea in children and adolescents. Li N, Zeng B Cai HE, Chen YH, Qiu MQ, Liu, MB, J. Hosp Infect 2018 Aug.;99(4):469-474.
3. Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, Wilson LE, Holzbauer SM, Phipps EC, Dumyati GK, Beldavs ZG, Kainer MA, Karlsson M, Gerding DN, McDonald LC. Trends in U.S. Burden of *Clostridioides difficile* Infection and Outcomes .N Engl J Med 2020 Apr;382(14):1320-1330.
4. Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent *Clostridium Difficile* Infection in the United States Clinical Infectious Disease Dongmu Zhang<sup>1</sup>, Vimalanand S Prabhu<sup>1</sup>, Stephen W Marcella 2018 Apr 17;66(9):1326-1332.
5. The burden of healthcare-associated *Clostridium difficile* infection in a non-metropolitan setting. Bond SE, Boutlis CS, Yeo WW, Pratt WAB, Orr ME, Miyakis S. J Hosp Infect. 2017 Apr;95(4):387-393.
6. Economic burden and cost -effective management of *Clostridium difficile* infections. Heimann SM, Cruz Aguilar MR, Mellinghof S, Vehreschild MJGT. Med Mal Infect. 2018 Feb;48(1):23-29.
7. Attributable healthcare resource utilization and costs for patients with primary and recurrent *Clostridium* infection in the United States. .Zhang D, Prabhu VS, Marcella SW. Clin Infect Dis. 2018 Apr 17;66(9):1326-1332.

8. Changes in outpatient use of antibiotics by adults in the United States 2006-2011. Mundkur ML, Franklin J, Huybrechts KF, Fischer MA, Kesselheim AS, Linder JA, Landon J, Patorno E. *Drug Saf.* 2018 Dec;41(12):1333-1342.
9. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits 2010-2011. Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File TM Jr, Finkelstein JA, Gerber JS, Hyun DY, Linder JA, Lynfield R, Margolis DJ, May LS, Merenstein D, Metlay JP, Newland JG, Piccirillo JF, Roberts RM, Sanchez GV, Suda KJ, Thomas A, Woo TM, Zetts RM, Hicks LA. *JAMA.* 2016 May 3;315(17):1864-73.
10. Clostridium difficile in Older adults. Donskey CJ. *Infect Dis Clin North Am.* 2017 Dec;31(4):724-756.
11. Probiotics for Gastrointestinal Conditions: A Summary of the Evidence Thad Wilkins<sup>1</sup>, Jacqueline Sequoia *Am Family Physician.* 2017 Aug 1;96(3):170-178.
12. Probiotics for the Prevention of Clostridium Difficile-Associated Diarrhea in Adults and Children Joshua Z Goldenberg<sup>1</sup>, Christina Yap, Lyubov Lytvyn, Calvin Ka-Fung Lo, Jennifer Beardsley, Dominik Mertz, Bradley C Johnston *Cochrane Database Sys Rev.* 2017 Dec 19;12(12):CD006095.
13. Probiotics for Prevention of Clostridium Difficile Infection John P Mills<sup>1</sup>, Krishna Rao<sup>1</sup>, Vincent B Young<sup>1</sup> *Curr Opin Gastroenterol.* 2018 Jan;34(1):3-10.
14. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Johnston BC, Ma SS, Goldenberg JZ, Thorlund K, Vandvik PO, Loeb M, Guyatt GH. *Ann Intern Med.* 2012 Dec 18;157(12):878-88.

15. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Goldenberg JZ, Ma SS, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, Guyatt GH, Johnston BC. Cochrane Database Syst Rev. 2013 May 31;(5):CD006095
16. Probiotics and prevention of Clostridium difficile infection. Goldstein EJC, Johnson SJ, Maziade PJ, Evans CT, Sniffen JC, Millette M, McFarland LV. Anaerobe. 2017 Jun;45:114-119.
17. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. O'Toole PW, Marchesi JR, Hill C. Nat Microbiol. 2017 Apr 25;2:17057
18. Next generation probiotics in disease amelioration. Chang CJ, Lin TL, Tsai YL, Wu TR, Lai WF, Lu CC, Lai HC. J Food Drug Anal. 2019 Jul;27(3):615-622.
19. Harvard School of Public Health, The Nutrition Source, The Microbiome, 2020.
20. Spores of Bacillus coagulans GBI-30, 6086 show high germination, survival and enzyme activity in a dynamic, computer-controlled in vitro model of the gastrointestinal tract. Keller D, Verbruggen S, Cash H, Farmer S, Venema K. Benef Microbes. 2019 Feb 8;10(1):77-87
21. Survival and metabolic activity of the GanedenBC30 strain of Bacillus coagulans in a dynamic in vitro model of the stomach and small intestine.  
Maathuis AJ, Keller D, Farmer S. Benef Microbes. 2010 Mar;1(1):31-6
22. Survival of probiotics in pea protein-alginate microcapsules with or without chitosan coating during storage and in a simulated gastrointestinal

- environment. Varankovich N, Martinez MF, Nickerson MT, Korber DR. *Food Sci Biotechnol.* 2017 Feb 28;26(1):189-194.
23. Extending Viability of *Bifidobacterium longum* in Chitosan-Coated Alginate Microcapsules Using Emulsification and Internal Gelation Encapsulation Technology. Rui Ji R, Wu J, Zhang J, Wang T, Zhang X, Shao L, Chen D, Wang J. *Front Microbiol.* 2019 Jun 28;10:1389.
24. An improved method of microencapsulation of probiotic bacteria for their stability in acidic and bile conditions during storage. Ding WK, Shah NP. *J Food Sci.* 2009 Mar;74(2):M53-61
25. Physiological protection of probiotic microcapsules by coatings. Ramos PE, Cerqueira MA, Teixeira JA, Vicente AA. *Crit Rev Food Sci Nutr.* 2018 Jul 24;58(11):1864-1877.
26. FDA Policy Regarding Quantitative Labeling of Dietary Supplements Containing Live Microbials: Guidance for Industry 21 CFR 10.115(g)(5))
27. Engineering Diagnostic and Therapeutic Gut Bacteria. Landry BP, Tabor JJ. *Microbiol Spectr.* 2017 Oct;5(5).
28. Emerging Trends in "Smart Probiotics": Functional Consideration for the Development of Novel Health and Industrial Applications. El Hage R, Hernandez-21. Sanabria E, Van de Wiele T. *Front Microbiol.* 2017 Sep 29;8:1889.
29. Horizontal gene transfer: building the web of life. Soucy SM, Huang J<sup>2</sup>, Gogarten JP<sup>3</sup>. *Nat Rev Genet.* 2015 Aug;16(8):472-82.
30. Lateral gene transfer and the nature of bacterial innovation. Ochman H, Lawrence JG, Groisman EA. *Nature.* 2000 May 18;405(6784):299-304.

31. The chromosomal organization of horizontal gene transfer in bacteria. Olivera, PH, Touchon M<sup>3,4</sup>, Cury J<sup>5</sup>, Rocha EPC Nat. Comm 2017 Oct 10;8(1):841.
32. Current understanding of the human microbiome. Gilbert JA, Blaser MJ<sup>4</sup>, Caporaso JG, Jansson JK, Lynch SV<sup>7</sup>, Knight R. Nat Med. 2018 Apr 10;24(4):392-400.
33. Bacterial contact-dependent delivery systems. Hayes CS, Aoki SK, Low DA. Annu Rev Genet. 2010;44:71-90.
34. The Human Gut Phage Community and Its Implications for Health and Disease. Manrique P, Dills M<sup>2</sup>, Young MJ<sup>3</sup>. Viruses.2017 Jun 8;9(6).
35. Acid tolerance of bacteria used in Doctors Biome™ DCUSA, Danisco, USA, Inc. subsidiary of Dupont.
36. Su GL, Ko CW, Bercik P, Falck-Ytter Y, Sultan S, Weizman AV, Morgan RL, AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders, Gastroenterology (2020), doi: <https://doi.org/10.1053/j.gastro.2020.05.059>.

## **ACKNOWLEDGMENT**

Authors acknowledge the valuable contribution of Mary Lee Kluger and Andrew Liles from the independent Certified Laboratories (Melville, New York) for microbiological tests.

## **FINANCIAL DISCLOSURE**

Dr. Kamarei was paid as a consultant. Certified Laboratories was monetarily compensated by Doctor's Biome microbiological tests.

## **CONFLICT OF INTEREST**

Dr. Robins and Dr. Kamarei are partners in Doctor's Biome Company (Newgen 27 LLC).

**Table 1a) Bifidobacteria of Doctor's Biome Colon Health**  
(registered trademarks of DuPont-Danisco)

Bifidobacterium bifidum Bb-06	This is a specially selected strains of Bifidobacterium bifidum that could be used with a variety of excipients.
Bifidobacterium breve Bb-03	This strain is a specially selected strain of Bifidobacterium breve. B. breve (Bb-03) has demonstrated very good adhesion to human epithelial cell lines (HT-29) applied in in vitro studies. Bb-03 is tolerant to low pH conditions and survives the presence of bile at concentrations present in the duodenum.
Bifidobacterium lactis Bi-07®	This strain is a specially selected strain of Bifidobacterium lactis that could be part of a multiple strain custom blend with a variety of excipients. BI-07 has strong adhesion to intestinal cell lines.
Bifidobacterium longum BI-05	This is a specially selected strain of Bifidobacterium longum. In vitro studies have shown that B. longum BI-05 is tolerant to low pH conditions and survives the presence of bile at the concentrations present in the duodenum. B. longum BI-05 has demonstrated very good adhesion to human epithelial cell lines applied in in-vitro studies.
Bifidobacterium infantis Bi-26	This is a specially selected strain of Bifidobacterium longum subsp. infantis that could be part of a multiple strain custom blend with a variety of excipients.

**Table 1b) Lactobacilli of Doctor's Biome Colon Health**  
(registered trademarks of DuPont-Danisco)

Lactobacillus acidophilus La-14®	This strain is a specially selected strain of Lb. acidophilus. Well-suited for intestinal survival it has a high tolerance to gastrointestinal conditions (acid, bile, pepsin and pancreatin). LA-14 also has strong adhesion to intestinal cell lines. LA-14 may influence immune regulation as demonstrated by the induction of IL-12 and moderate induction of tumor necrosis factors in vitro.
Lactobacillus brevis Lbr-35	This is a specially selected strain of Lb. brevis that could be part of a multiple strain custom blend with a variety of excipients.
Lactobacillus bulgaricus Lb-87	This strain is a specially selected strain of Lb. bulgaricus. L. bulgaricus metabolizes and produces D (-)-lactic acid from four sugars: lactose, glucose, fructose and mannose. LB-87 has the ability to rapidly convert lactose into lactic acid. LB-87 also has the ability to convert lactose into lactate, aiding in lactose digestion.
Lactobacillus casei Lc-11®	This strain is a specially selected strain of Lb. casei. LC-11 is well suited for intestinal survival and functionality. It is highly tolerant of acid and bile. LC-11 adheres strongly to intestinal Caco-2 cell lines and it inhibits common pathogens.
Lactobacillus gasseri Lg-36	This strain is a specially selected strain of Lb. gasseri that could be part of a multiple strain custom blend with a variety of excipients.
Lactobacillus paracasei Lpc-37®	This strain is a specially selected strain of Lb. paracasei. Lpc-37 displayed in vitro inhibition of selected pathogens including Salmonella typhimurium, Staphylococcus aureus, Escherichia coli and Listeria monocytogenes. A five-strain formulation including L. paracasei (Lpc-37) was found to maintain and more rapidly restore microbiota after antibiotic treatment. LPC-37 is well-suited for intestinal survival, it has a high tolerance to gastrointestinal conditions (acid and bile).



Lactobacillus plantarum Lp-115®	This strain is a specially selected strain of Lb. plantarum. In vitro studies have shown that L. plantarum (Lp-115) is extremely resistant to low pH conditions and survives the presence of bile at concentrations present in the duodenum. Lp-115 displayed in vitro inhibition of selected pathogens including Salmonella typhimurium, Staphylococcus aureus, Escherichia coli and Listeria monocytogenes. LP-115 is well-suited for intestinal survival; it has a high tolerance to gastrointestinal conditions (acid, bile, pepsin and pancreatin) and has strong adhesion to intestinal cell lines. LP-115 may improve specific immune response, as demonstrated in a human clinical study.
Lactobacillus reuteri 1E1	This is a specially selected strain of Lactobacillus reuteri that could be part of a multiple strain custom blend with a variety of excipients.
Lactobacillus rhamnosus Lr-32®	This strain is a specially selected strain of Lb. rhamnosus. L. rhamnosus (Lr-32) has shown anti-inflammatory properties, as demonstrated through significant protection against TNBS induced colitis in an animal model. L. rhamnosus (Lr-32) may influence immune regulation, as demonstrated by the increased induction of IL-10 in vitro.
Lactobacillus salivarius Ls-33®	This is a specially selected strain of Lb. salivarius. LS-33 is well-suited for intestinal survival, it has a high tolerance to gastrointestinal conditions (acid, bile, pepsin and pancreatin). LS-33 has a strong adhesion to intestinal cell lines, and ability to inhibit common pathogens. It also has a beneficial modulation of immune functions, it may influence immune regulation, as demonstrated by increased induction of IL-10 in vitro.

**Table 2) Colony Counts of Clostridium difficile**

<b>Dilution</b>	<b>C o n t r o l</b>		<b>S a m p l e</b>	
	<b>Rep 1</b>	<b>Rep 2</b>	<b>Rep 1</b>	<b>Rep 2</b>
10 <sup>-1</sup>	TNTC	TNTC	0	0
10 <sup>-2</sup>	TNTC	TNTC	0	0
10 <sup>-3</sup>	TNTC	TNTC	0	0
10 <sup>-4</sup>	TNTC	TNTC	0	0
10 <sup>-5</sup>	TNTC	TNTC	0	0
10 <sup>-6</sup>	62	40	0	0
10 <sup>-7</sup>	3	1	0	0
10 <sup>-8</sup>	0	0	0	0

TNTC = Too Numerous To Count

**Fig 1)** Clostridium difficile (“*C. diff.*”)

Source: US Center for Disease Control and Prevention (CDC)

**Fig 2)** Doctor’s Biome Colon Health™

(a patent-pending blend of 15 strains of probiotics in organic vegetable/fruit juice)

**Fig 3)** Doctor’s Biome Colon Health pre-centrifugation

**Fig 4)** Doctor’s Biome Colon Health post-centrifugation/microfiltration

**Fig 5)** Presence of *C. diff.* colony forming units when Peptone Buffer is used  
for serial dilution.

**Fig 6)** Absence of *C. diff.* colony forming units when Doctor’s Biome Colon Health  
supernatant is used for serial dilution.